Mercer Global Advisors
XBI icon

Mercer Global Advisors’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Mercer Global Advisors’s Portfolio XBI Stock Details XBI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.83M Buy
14,350
+1,157
+9% +$144K ﹤0.01% 1232
2025
Q4 		$1.61M Sell
13,193
-2,337
-15% -$268K ﹤0.01% 1218
2025
Q3 		$1.56M Buy
15,530
+4,086
+36% +$368K ﹤0.01% 1147
2025
Q2 		$949K Sell
11,444
-5,047
-31% -$403K ﹤0.01% 1251
2025
Q1 		$1.34M Buy
16,491
+3,751
+29% +$335K ﹤0.01% 990
2024
Q4 		$1.15M Buy
12,740
+1,651
+15% +$160K ﹤0.01% 1042
2024
Q3 		$1.09M Sell
11,089
-39
-0.4% -$3.83K ﹤0.01% 987
2024
Q2 		$1.03M Buy
11,128
+3,214
+41% +$288K ﹤0.01% 954
2024
Q1 		$749K Buy
7,914
+1,169
+17% +$108K ﹤0.01% 1083
2023
Q4 		$602K Sell
6,745
-120
-2% -$8.91K ﹤0.01% 1214
2023
Q3 		$501K Sell
6,865
-1,575
-19% -$126K ﹤0.01% 1251
2023
Q2 		$702K Buy
8,440
+435
+5% +$36.4K ﹤0.01% 1082
2023
Q1 		$610K Sell
8,005
-1,732
-18% -$144K ﹤0.01% 1105
2022
Q4 		$808K Buy
9,737
+2,622
+37% +$212K ﹤0.01% 1003
2022
Q3 		$564K Buy
7,115
+1,038
+17% +$87.5K ﹤0.01% 1078
2022
Q2 		$451K Sell
6,077
-3,934
-39% -$295K ﹤0.01% 1198
2022
Q1 		$900K Buy
10,011
+1,113
+13% +$103K 0.01% 940
2021
Q4 		$996K Buy
8,898
+60
+0.7% +$7.24K 0.01% 885
2021
Q3 		$1.11M Sell
8,838
-1
-0% -$129 0.01% 812
2021
Q2 		$1.2M Buy
8,839
+665
+8% +$87.4K 0.01% 758
2021
Q1 		$1.11M Buy
8,174
+3,850
+89% +$576K 0.01% 748
2020
Q4 		$609K Sell
4,324
-696
-14% -$89.1K 0.01% 792
2020
Q3 		$559K Buy
5,020
+1,125
+29% +$126K 0.01% 753
2020
Q2 		$436K Buy
3,895
+357
+10% +$35.2K 0.01% 729
2020
Q1 		$274K Sell
3,538
-117
-3% -$10.4K 0.01% 839
2019
Q4 		$348K Sell
3,655
-1,550
-30% -$134K 0.01% 864
2019
Q3 		$396K Buy
5,205
+165
+3% +$13.7K 0.01% 783
2019
Q2 		$442K Buy
5,040
+1,024
+25% +$87.3K 0.01% 729
2019
Q1 		$364K Buy
+4,016
New +$342K 0.01% 756

Other funds holding XBI

BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $62.2B AUM 31.35% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Mercer Global Advisors's XBI Position: Q1 2026 in Review

Mercer Global Advisors increased its State Street SPDR S&P Biotech ETF (XBI) stake by 8.8% in Q1 2026, buying an estimated $144K and bringing the position to 14,350 shares worth $1.83M. The position accounts for ﹤0.01% of the portfolio, ranked #1232.

Mercer Global Advisors first reported a position in XBI in Q1 2019 and has held it in 29 quarters since. 813 funds tracked by Wall St. Rank hold XBI as of Q1 2026.

  • Mercer Global Advisors held 14,350 shares of State Street SPDR S&P Biotech ETF worth $1.83M as of Q1 2026.
  • Mercer Global Advisors bought 1,157 State Street SPDR S&P Biotech ETF shares in Q1 2026, an estimated $144K.
  • State Street SPDR S&P Biotech ETF made up ﹤0.01% of Mercer Global Advisors's portfolio in Q1 2026, its #1232 holding.
  • Mercer Global Advisors first reported a position in State Street SPDR S&P Biotech ETF in Q1 2019 and has held it in 29 quarters since.
  • 813 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q1 2026.

Based on Mercer Global Advisors's 13F filing for Q1 2026, filed 15 May 2026.